Cytokinetics aims to become the Vertex of cardiovascular disease
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
